OBJECTIVES: To optimize empirical treatment of urinary tract infections (UTIs), regular evaluation of the antibiotic susceptibility of the most common uropathogen, Escherichia coli, is necessary. We compared the antibiotic prescription rate for UTIs in women and the E. coli antibiotic susceptibility results, including the prevalence of extended-spectrum β-lactamase (ESBL)-producing strains, in 2009 with data collected 5 years earlier. PATIENTS AND METHODS: Urinary samples from female patients with symptoms of uncomplicated UTI in 42 general practices were collected over a 6 month period. Uropathogens were identified and the antibiotic susceptibility of E. coli was determined. RESULTS: We analysed 970 urine cultures, of which 785 (81%) were considered positive (≥ 10(3) cfu/mL). E. coli accounted for 72% of the isolates. ESBLs showed an increase between the two surveys (0.1% versus 1%; P < 0.001), while no difference in antibiotic susceptibility to the commonly used antimicrobial agents for UTIs was observed. A significantly lower susceptibility rate to co-amoxiclav was observed in the eastern region of the Netherlands, as compared with the northern region (80% versus 92%; P < 0.05). Consistent with national guidelines, the prescription rate of trimethoprim decreased over time (19% versus 5%; P < 0.05) whereas nitrofurantoin and fosfomycin rates showed an increase (58% versus 66% and 0% versus 6% respectively, both P < 0.05). CONCLUSIONS: Over a 5 year period, the antibiotic susceptibility of uropathogenic E. coli did not change in female patients with uncomplicated UTI in the Netherlands, but ESBL prevalence increased. With respect to the prescription of antimicrobial agents, compliance with national UTI guidelines was good.
OBJECTIVES: To optimize empirical treatment of urinary tract infections (UTIs), regular evaluation of the antibiotic susceptibility of the most common uropathogen, Escherichia coli, is necessary. We compared the antibiotic prescription rate for UTIs in women and the E. coli antibiotic susceptibility results, including the prevalence of extended-spectrum β-lactamase (ESBL)-producing strains, in 2009 with data collected 5 years earlier. PATIENTS AND METHODS: Urinary samples from female patients with symptoms of uncomplicated UTI in 42 general practices were collected over a 6 month period. Uropathogens were identified and the antibiotic susceptibility of E. coli was determined. RESULTS: We analysed 970 urine cultures, of which 785 (81%) were considered positive (≥ 10(3) cfu/mL). E. coli accounted for 72% of the isolates. ESBLs showed an increase between the two surveys (0.1% versus 1%; P < 0.001), while no difference in antibiotic susceptibility to the commonly used antimicrobial agents for UTIs was observed. A significantly lower susceptibility rate to co-amoxiclav was observed in the eastern region of the Netherlands, as compared with the northern region (80% versus 92%; P < 0.05). Consistent with national guidelines, the prescription rate of trimethoprim decreased over time (19% versus 5%; P < 0.05) whereas nitrofurantoin and fosfomycin rates showed an increase (58% versus 66% and 0% versus 6% respectively, both P < 0.05). CONCLUSIONS: Over a 5 year period, the antibiotic susceptibility of uropathogenic E. coli did not change in female patients with uncomplicated UTI in the Netherlands, but ESBL prevalence increased. With respect to the prescription of antimicrobial agents, compliance with national UTI guidelines was good.
Authors: I M Cullen; R P Manecksha; E McCullagh; S Ahmad; F O'Kelly; R Flynn; T E D McDermott; P Murphy; R Grainger; J P Fennell; J A Thornhill Journal: Ir J Med Sci Date: 2012-06-06 Impact factor: 1.568
Authors: T N Platteel; M A Leverstein-Van Hall; J W Cohen Stuart; G M Voets; M P van den Munckhof; J Scharringa; N van de Sande; A C Fluit; M J M Bonten Journal: Eur J Clin Microbiol Infect Dis Date: 2013-03-22 Impact factor: 3.267
Authors: Evelien M E van Bijnen; Casper D J den Heijer; W John Paget; Ellen E Stobberingh; Robert A Verheij; Cathrien A Bruggeman; Mike Pringle; Herman Goossens; François G Schellevis Journal: BMC Infect Dis Date: 2011-10-28 Impact factor: 3.090
Authors: Senthilkumar Palaniyandi; Arindam Mitra; Christopher D Herren; C Virginia Lockatell; David E Johnson; Xiaoping Zhu; Suman Mukhopadhyay Journal: PLoS One Date: 2012-02-21 Impact factor: 3.240
Authors: Hetty Blaak; Angela H A M van Hoek; Raditijo A Hamidjaja; Rozemarijn Q J van der Plaats; Lianne Kerkhof-de Heer; Ana Maria de Roda Husman; Franciska M Schets Journal: PLoS One Date: 2015-08-13 Impact factor: 3.240
Authors: Christina F M van der Donk; Jeroen H B van de Bovenkamp; Els I G B De Brauwer; Patrick De Mol; Karl-Heinz Feldhoff; Wiltrud M Kalka-Moll; Sita Nys; Inge Thoelen; Thera A M Trienekens; Ellen E Stobberingh Journal: PLoS One Date: 2012-10-17 Impact factor: 3.240
Authors: Casper D J den Heijer; John Penders; Gé A Donker; Cathrien A Bruggeman; Ellen E Stobberingh Journal: PLoS One Date: 2013-03-29 Impact factor: 3.240